Functions for platelet factor 4 (PF4/CXCL4) and its receptors in fibroblast-myofibroblast transition and fibrotic failure of arteriovenous fistulas (AVFs)
Restricted accessResearch articleFirst published online November, 2024
Functions for platelet factor 4 (PF4/CXCL4) and its receptors in fibroblast-myofibroblast transition and fibrotic failure of arteriovenous fistulas (AVFs)
Over 60% of End Stage Renal Disease (ESRD) patients are relying on hemodialysis (HD) to survive, and the arteriovenous fistula (AVF) is the preferred vascular access method for HD. However approximately half of all newly created AVF fail to mature and cannot be used without a salvage procedure. We have recently demonstrated an association between AVF maturation failure and post-operative fibrosis, while our RNA-seq study also revealed that veins that ultimately failed during AVF maturation had elevated levels of platelet factor 4 (PF4/CXCL4). However, a link between these two findings was yet to be established.
Methods:
In this study, we investigated potential mechanisms between PF4 levels and fibrotic remodeling in veins. We compared the local expression of PF4 and fibrosis marker integrin β6 (ITGB6) in veins that successfully underwent maturation with that in veins that ultimately failed to mature. We also measured the changes of expression level of α-smooth muscle actin (αSMA/ACTA2) and collagen (Col1/COL1A1) in venous fibroblasts upon various treatments, such as PF4 pharmacological treatment, alteration of PF4 expression, and blocking of PF4 receptors.
Results:
We found that PF4 is expressed in veins and co-localizes with αSMA. In venous fibroblasts, PF4 stimulates expression of αSMA and Col1 via different pathways. The former requires integrins αvβ5 and α5β1, while chemokine receptor CXCR3 is needed for the latter. Interestingly, we also discovered that the expression of PF4 is associated with that of ITGB6, the β subunit of integrin αvβ6. This integrin is critical for the activation of the major fibrosis factor TGFβ, and overexpression of PF4 promotes activation of the TGFβ pathway.
Conclusions:
These results indicate that upregulation of PF4 may cause venous fibrosis both directly by stimulating fibroblast differentiation and expression of extracellular matrix (ECM) molecules and indirectly by facilitating the activation of the TGFβ pathway.
System USRD. USRDS Annual Data Report: Epidemiology of kidney disease in the United States. Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 2020.
2.
NassarGMAyusJC.Infectious complications of the hemodialysis access. Kidney Int2001; 60(1): 1–13.
3.
RamanathanVChiuEJThomasJT, et al. Healthcare costs associated with hemodialysis catheter–related infections: a single-center experience. Infect Control Hosp Epidemiol2007; 28(05): 606–609.
4.
WooKDorosGNgT, et al. Comparison of the efficacy of upper arm transposed arteriovenous fistulae and upper arm prosthetic grafts. J Vasc Surg2009; 50(6): 1405–11.e1.
5.
Al-JaishiAAOliverMJThomasSM, et al. Patency rates of the arteriovenous fistula for hemodialysis: a systematic review and meta-analysis. Am J Kidney Dis2014; 63(3): 464–478.
MayaIDO’NealJCYoungCJ, et al. Outcomes of brachiocephalic fistulas, transposed brachiobasilic fistulas, and upper arm grafts. Clin J Am Soc Nephrol2009; 4(1): 86–92.
8.
RavaniPSpergelLMAsifA, et al. Clinical epidemiology of arteriovenous fistula in 2007. J Nephrol2007; 20(2): 141–149.
9.
DemberLMBeckGJAllonM, et al. Effect of clopidogrel on early failure of arteriovenous fistulas for hemodialysis: a randomized controlled trial. JAMA2008; 299(18): 2164–2171.
10.
LokCEAllonMMoistL, et al. Risk equation determining unsuccessful cannulation events and failure to maturation in arteriovenous fistulas (REDUCE FTM I). J Am Soc Nephrol2006; 17(11): 3204–3212.
11.
MartinezLDuqueJCTabbaraM, et al. Fibrotic venous remodeling and nonmaturation of arteriovenous fistulas. J Am Soc Nephrol2018; 29(3): 1030–1040.
12.
HendersonNCRiederFWynnTA.Fibrosis: from mechanisms to medicines. Nature2020; 587(7835): 555–566.
13.
RockeyDCBellPDHillJA.Fibrosis — A common pathway to organ injury and failure. New Engl J Med2015; 372(12): 1138–1149.
14.
WynnTA.Integrating mechanisms of pulmonary fibrosis. J Exp Med2011; 208(7): 1339–1350.
15.
LanTHHuangXQTanHM.Vascular fibrosis in atherosclerosis. Cardiovasc Pathol2013; 22(5): 401–407.
16.
MarkellaPBarbaraD.Extracellular matrix synthesis in vascular disease: hypertension, and atherosclerosis. J Biomed Res2014; 28(1): 25–39.
17.
TouyzRM.Intracellular mechanisms involved in vascular remodelling of resistance arteries in hypertension: role of angiotensin II. Exp Physiol2005; 90(4): 449–455.
18.
BiernackaADobaczewskiMFrangogiannisNG.TGF-β signaling in fibrosis. Growth Factors2011; 29(5): 196–202.
19.
LeaskAAbrahamDJ.TGF-β signaling and the fibrotic response. FASEB J2004; 18(7): 816–827.
20.
MengXMNikolic-PatersonDJLanHY.TGF-β: the master regulator of fibrosis. Nat Rev Nephrol2016; 12(6): 325–338.
21.
PiersmaBBankRABoersemaM.Signaling in fibrosis: TGF-β, WNT, and YAP/TAZ converge. Front Med2015; 2: 59.
22.
MungerJSHuangXKawakatsuH, et al. A mechanism for regulating pulmonary inflammation and fibrosis: the integrin αvβ6 binds and activates latent TGF β1. Cell1999; 96(3): 319–328.
23.
EmingSAMartinPTomic-CanicM.Wound repair and regeneration: mechanisms, signaling, and translation. Sci Transl Med2014; 6(265): 265sr6.
24.
MartinezLTabbaraMDuqueJC, et al. Transcriptomics of human arteriovenous fistula failure: genes associated with nonmaturation. Am J Kidney Dis2019; 74(1): 73–81.
25.
Silva-CardosoSCTaoWAngiolilliC, et al. CXCL4 links inflammation and fibrosis by reprogramming monocyte-derived dendritic cells in vitro. Front Immunol2020; 11: 2149.
26.
GleitzHFEDugourdAJFLeimkühlerNB, et al. Increased CXCL4 expression in hematopoietic cells links inflammation and progression of bone marrow fibrosis in MPN. Blood2020; 136(18): 2051–2064.
27.
LandeRLeeEYPalazzoR, et al. CXCL4 assembles DNA into liquid crystalline complexes to amplify TLR9-mediated interferon-α production in systemic sclerosis. Nat Commun2019; 10(1): 1731.
28.
van BonLAffandiAJBroenJ, et al. Proteome-wide analysis and CXCL4 as a biomarker in systemic sclerosis. New Engl J Med2014; 370(5): 433–443.
29.
VolkmannERTashkinDPRothMD, et al. Changes in plasma CXCL4 levels are associated with improvements in lung function in patients receiving immunosuppressive therapy for systemic sclerosis-related interstitial lung disease. Arthritis Res Ther2016; 18(1): 305.
30.
XiaoYVazquez-PadronRIMartinezL, et al. Role of platelet factor 4 in arteriovenous fistula maturation failure: What do we know so far?J Vasc Access2022: 11297298221085458. Online ahead of print.
31.
LamarJMXiaoYNortonE, et al. SRC tyrosine kinase activates the YAP/TAZ axis and thereby drives tumor growth and metastasis. J Biol Chem2019; 294(7): 2302–2317.
32.
KopecAMRiveraPDLacagninaMJ, et al. Optimized solubilization of trizol-precipitated protein permits western blotting analysis to maximize data available from brain tissue. J Neurosci Methods2017; 280: 64–76.
33.
FuruyaMTanakaRMiyagiE, et al. Impaired CXCL4 expression in tumor-associated macrophages (TAMs) of ovarian cancers arising in endometriosis. Cancer Biol Ther2012; 13(8): 671–680.
34.
MaierMGeigerEVHenrichD, et al. Platelet factor 4 is highly upregulated in dendritic cells after severe trauma. Mol Med2009; 15(11-12): 384–391.
35.
RavidKBeelerDLRabinMS, et al. Selective targeting of gene products with the megakaryocyte platelet factor 4 promoter. Proc Natl Acad Sci USA1991; 88(4): 1521–1525.
36.
SchaffnerARhynPSchoedonG, et al. Regulated expression of platelet factor 4 in human monocytes—role of PARs as a quantitatively important monocyte activation pathway. J Leukoc Biol2005; 78(1): 202–209.
37.
LiLTerryCMBlumenthalDK, et al. Cellular and morphological changes during neointimal hyperplasia development in a porcine arteriovenous graft model. Nephrol Dial Transplant2007; 22(11): 3139–3146.
38.
MisraSDohertyMGWoodrumD, et al. Adventitial remodeling with increased matrix metalloproteinase-2 activity in a porcine arteriovenous polytetrafluoroethylene grafts. Kidney Int2005; 68(6): 2890–2900.
39.
AidoudiSBikfalviA.Interaction of PF4 (CXCL4) with the vasculature: a role in atherosclerosis and angiogenesis. Thromb Haemost2010; 104(11): 941–948.
40.
FoxJMKausarFDayA, et al. CXCL4/Platelet factor 4 is an agonist of CCR1 and drives human monocyte migration. Sci Rep2018; 8(1): 9466.
41.
LasagniLFrancalanciMAnnunziatoF, et al. An alternatively spliced variant of CXCR3 mediates the inhibition of endothelial cell growth induced by IP-10, Mig, and I-TAC, and acts as functional receptor for platelet factor 4. J Exp Med2003; 197(11): 1537–1549.
42.
LishkoVKYakubenkoVPUgarovaTP, et al. Leukocyte integrin Mac-1 (CD11b/CD18, αMβ2, CR3) acts as a functional receptor for platelet factor 4. J Biol Chem2018; 293(18): 6869–6882.
43.
MuellerAMeiserAMcDonaghEM, et al. CXCL4-induced migration of activated T lymphocytes is mediated by the chemokine receptor CXCR3. J Leukoc Biol2008; 83(4): 875–882.
44.
SachaisBSKuoANassarT, et al. Platelet factor 4 binds to low-density lipoprotein receptors and disrupts the endocytic itinerary, resulting in retention of low-density lipoprotein on the cell surface. Blood2002; 99(10): 3613–3622.
WhitsonRHWongWLItakuraK.Platelet factor 4 selectively inhibits binding of TGF-β1 to the type I TGF-β1 receptor. J Cell Biochem1991; 47(1): 31–42.
47.
GallianoMFToulzaEJoncaN, et al. Binding of α2ML1 to the low density lipoprotein receptor-related protein 1 (LRP1) reveals a new role for LRP1 in the human epidermis. PLoS One2008; 3(7): e2729.
48.
GrzeszkiewiczTMKirschlingDJChenN, et al. CYR61 stimulates human skin fibroblast migration through integrin αvβ5 and enhances mitogenesis through integrin αvβ3, independent of its carboxyl-terminal domain. J Biol Chem2001; 276(24): 21943–21950.
49.
LinCGChenCCLeuSJ, et al. Integrin-dependent functions of the angiogenic inducer NOV (CCN3): implication in wound healing. J Biol Chem2005; 280(9): 8229–8237.
50.
Revuelta-LópezESoler-BotijaCNasarreL, et al. Relationship among LRP1 expression, Pyk2 phosphorylation and MMP-9 activation in left ventricular remodelling after myocardial infarction. J Cell Mol Med2017; 21(9): 1915–1928.
51.
SchniederJMamazhakypovABirnhuberA, et al. Loss of LRP1 promotes acquisition of contractile-myofibroblast phenotype and release of active TGF-β1 from ECM stores. Matrix Biol2020; 88: 69–88.
52.
AnSYJangYJLimHJ, et al. Milk fat globule-egf factor 8, secreted by mesenchymal stem cells, protects against liver fibrosis in mice. Gastroenterology2017; 152(5): 1174–1186.
53.
HuKWuCMarsWM, et al. Tissue-type plasminogen activator promotes murine myofibroblast activation through LDL receptor–related protein 1–mediated integrin signaling. J Clin Investig2007; 117(12): 3821–3832.
54.
PickeringJGChowLHLiS, et al. α5β1 integrin expression and luminal edge fibronectin matrix assembly by smooth muscle cells after arterial injury. Am J Pathol2000; 156(2): 453–465.
55.
YangMHuangHLiJ, et al. Tyrosine phosphorylation of the LDL receptor-related protein (LRP) and activation of the ERK pathway are required for connective tissue growth factor to potentiate myofibroblast differentiation. FASEB J2004; 18(15): 1920–1921.
56.
ZuckerMMWujakLGunglA, et al. LRP1 promotes synthetic phenotype of pulmonary artery smooth muscle cells in pulmonary hypertension. Biochim Biophys Acta Mol Basis Dis2019; 1865(6): 1604–1616.
57.
PrasadJMMiglioriniMGalisteoR, et al. Generation of a potent low density lipoprotein receptor-related protein 1 (LRP1) antagonist by engineering a stable form of the receptor-associated protein (RAP) D3 domain. J Biol Chem2015; 290(28): 17262–17268.
58.
HariharanSGustafsonDHoldenS, et al. Assessment of the biological and pharmacological effects of the ανβ3 and ανβ5 integrin receptor antagonist, cilengitide (EMD 121974), in patients with advanced solid tumors. Ann Oncol2007; 18(8): 1400–1407.
KhanZMarshallJF.The role of integrins in TGFβ activation in the tumour stroma. Cell Tissue Res2016; 365(3): 657–673.
61.
LiuCTHsuSCHsiehHL, et al. Parathyroid hormone induces transition of myofibroblasts in arteriovenous fistula and increases maturation failure. Endocrinology2021; 162(7): 1–15.
62.
TatlerALGoodwinATGbolahanO, et al. Amplification of TGFβ induced ITGB6 gene transcription may promote pulmonary fibrosis. PLoS One2016; 11(8): e0158047.
63.
TesfamariamB.Periadventitial local drug delivery to target restenosis. Vasc Pharmacol2018; 107: 12–19.
64.
WangYKrishnamoorthyMBanerjeeR, et al. Venous stenosis in a pig arteriovenous fistula model—anatomy, mechanisms and cellular phenotypes. Nephrol Dial Transplant2007; 23(2): 525–533.
65.
KorniejewskaAMcKnightAJJohnsonZ, et al. Expression and agonist responsiveness of CXCR3 variants in human T lymphocytes. Immunology2011; 132(4): 503–515.
66.
WuQDhirRWellsA.Altered CXCR3 isoform expression regulates prostate cancer cell migration and invasion. Mol Cancer2012; 11: 3.
67.
BrahmbhattANievesTorresEYangB, et al. The role of iex-1 in the pathogenesis of venous neointimal hyperplasia associated with hemodialysis arteriovenous fistula. PLoS One2014; 9(7): e102542.
68.
LindseyMLJungMYabluchanskiyA, et al. Exogenous CXCL4 infusion inhibits macrophage phagocytosis by limiting CD36 signalling to enhance post-myocardial infarction cardiac dilation and mortality. Cardiovasc Res2019; 115(2): 395–408.
69.
IidaYXuBXuanH, et al. Peptide inhibitor of CXCL4–CCL5 heterodimer formation, MKEY, inhibits experimental aortic aneurysm initiation and progression. Arterioscler Thromb Vasc Biol2013; 33(4): 718–726.
70.
GouwyMRuytinxPRadiceE, et al. CXCL4 and CXCL4L1 differentially affect monocyte survival and dendritic cell differentiation and phagocytosis. PLoS One2016; 11(11): e0166006.
71.
Van den SteenPEProostPWuytsA, et al. Neutrophil gelatinase B potentiates interleukin-8 tenfold by aminoterminal processing, whereas it degrades CTAP-III, PF-4, and GRO-alpha and leaves RANTES and MCP-2 intact. Blood2000; 96(8): 2673–2681.
72.
AgrezMGuXTurtonJ, et al. The alpha v beta 6 integrin induces gelatinase B secretion in colon cancer cells. Int J Cancer1999; 81(1): 90–97.
73.
NiuJGuXTurtonJ, et al. Integrin-mediated signalling of gelatinase B secretion in colon cancer cells. Biochem Biophys Res Commun1998; 249(1): 287–291.
74.
EberleinCRooneyCRossSJ, et al. E-cadherin and EpCAM expression by NSCLC tumour cells associate with normal fibroblast activation through a pathway initiated by integrin αvβ6 and maintained through TGFβ signalling. Oncogene2015; 34(6): 704–716.
75.
YangGYXuKSPanZQ, et al. Integrin alphavbeta6 mediates the potential for colon cancer cells to colonize in and metastasize to the liver. Cancer Sci2008; 99(5): 879–887.
76.
DesaiKNairMGPrabhuJS, et al. High expression of integrin β6 in association with the Rho-Rac pathway identifies a poor prognostic subgroup within HER2 amplified breast cancers. Cancer Med2016; 5(8): 2000–2011.
77.
LiZBiswasSLiangB, et al. Integrin β6 serves as an immunohistochemical marker for lymph node metastasis and promotes cell invasiveness in cholangiocarcinoma. Sci Rep2016; 6: 30081.
78.
LaboyrieSLde VriesMRde JongA, et al. von Willebrand factor: a central regulator of arteriovenous fistula maturation through smooth muscle cell proliferation and outward remodeling. J Am Heart Assoc2022; 11(16): e024581.
79.
JohnstonISarkarAHayesV, et al. Recognition of PF4-VWF complexes by heparin-induced thrombocytopenia antibodies contributes to thrombus propagation. Blood2020; 135(15): 1270–1280.
80.
DongJFMoakeJLNolascoL, et al. ADAMTS-13 rapidly cleaves newly secreted ultralarge von Willebrand factor multimers on the endothelial surface under flowing conditions. Blood2002; 100(12): 4033–4039.
81.
NazyIElliottTDArnoldDM.Platelet factor 4 inhibits ADAMTS13 activity and regulates the multimeric distribution of von Willebrand factor. Br J Haematol2020; 190(4): 594–598.
82.
Szóstek-MioduchowskaAKordowitzkiP.Shedding light on the possible link between ADAMTS13 and vaccine-induced thrombotic thrombocytopenia. Cells2021; 10(10): 2785.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
